Professional Summary
Professional Overview
Adam Bartnik is an accomplished finance executive with over 20 years of experience in the pharmaceutical and biotechnology industries. As the Chief Financial Officer at Reprieve Cardiovascular and a Principal Consultant at Ascend Bio Advisors LLC, he leverages his extensive expertise in financial planning, analysis, and portfolio management to drive strategic decision-making and operational excellence.
Experience Summary
Current Roles
Chief Financial Officer, Reprieve Cardiovascular (2024-08-01 to Present)
- Responsible for overseeing all financial aspects of the organization, including financial planning, reporting, and analysis
- Played a key role in securing $50 million in Series B funding to support the company's R&D efforts and commercial expansion
- Implemented robust financial controls and processes to ensure efficient resource allocation and cost management
Principal Consultant, Ascend Bio Advisors LLC (2024-04-01 to Present)
- Provides strategic financial advisory services to biotechnology and pharmaceutical companies
- Assists clients in financial modeling, portfolio optimization, and business development initiatives
- Leverages deep industry knowledge to help clients navigate complex regulatory and market dynamics
Career Progression
Vice President, R&D Finance, Vertex Pharmaceuticals (2019-10-01 to 2024-04-01)
- Managed the financial planning and analysis for the company's R&D portfolio, including budgeting, forecasting, and performance reporting
- Collaborated with cross-functional teams to optimize resource allocation and drive the successful development of new drug candidates
Vice President, Corporate Financial Planning & Analysis, Bristol-Myers Squibb (2019-02-01 to 2019-10-01)
- Oversaw the corporate FP&A function, providing strategic financial insights to senior leadership
- Played a key role in the integration of Celgene Corporation, ensuring a seamless transition and financial alignment
Executive Director - Head of Finance, R&D Portfolio Management and Analysis, Bristol-Myers Squibb (2016-07-01 to 2019-02-01)
- Led a team of finance professionals responsible for the financial management and analysis of the company's R&D portfolio
- Developed innovative reporting and decision-support tools to enhance the company's R&D investment strategies
Academic Background
Adam Bartnik holds a Master of Business Administration (MBA) from the Wharton School of the University of Pennsylvania, where he specialized in Finance and Accounting. He also earned a Bachelor of Science (BS) in Accounting from the University of Illinois at Urbana-Champaign.
Areas of Expertise
- Financial planning and analysis
- R&D portfolio management and optimization
- Mergers and acquisitions integration
- Strategic business advisory
- Pharmaceutical and biotechnology industry knowledge
Professional Impact
- Instrumental in securing $50 million in Series B funding for Reprieve Cardiovascular to support the company's growth
- Played a key role in the successful integration of Celgene Corporation into Bristol-Myers Squibb, ensuring financial alignment and operational continuity
- Developed innovative financial reporting and decision-support tools that enhanced R&D investment strategies at Bristol-Myers Squibb
Conclusion
With his extensive experience in the pharmaceutical and biotechnology sectors, Adam Bartnik is a seasoned finance executive who excels at driving strategic decision-making, optimizing resource allocation, and delivering tangible business impact. As he continues to excel in his current roles, he is poised to make significant contributions to the industry and positively impact the development of innovative healthcare solutions.
